IDXGD · Interpace Biosciences, Inc. · Insider Trading

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations.

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

On January 20, 2026, 28,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 13,861,386 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

These securities are held of record by Ampersand 2018 Limited Partnership (the "Investor"). AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

On January 20, 2026, 28,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 13,861,386 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

The Series C Preferred Shares had no expiration date.

These securities are held of record by Ampersand 2018 Limited Partnership (the "Investor"). AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

The Series C Convertible Preferred Stock had no expiration date.

These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Represents the net issuance of 1,111 shares from the vesting of 1,668 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 557 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

The shares of Series B Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B Preferred Shares") were convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B Preferred Share of $1,000 divided by a conversion price of $6.00 per share (the "Series B Conversion Price") and then multiplied by the number of Series B Preferred Shares to be converted. The Series B Preferred Shares had no expiration date.

On October 11, 2024, the Issuer exchanged all 19,000 existing shares of Series B Shares held by 1315 Capital II, L.P. (the "Investor") for 19,000 newly created shares of Series C Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series C Preferred Shares").

These securities are held of record by the Investor. 1315 Capital Management II, LLC ("1315 Capital Management") is the general partner of the Investor. By virtue of such relationship, 1315 Capital Management may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor and 1315 Capital Management disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

On October 11, 2024, the Issuer exchanged all 19,000 existing shares of Series B Shares held by 1315 Capital II, L.P. (the "Investor") for 19,000 newly created shares of Series C Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series C Preferred Shares").

The Series C Preferred Shares are convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by an initial conversion price of $2.02 per share and then multiplied by the number of Series C Preferred Shares to be converted. The Series C Preferred Shares have no expiration date.

These securities are held of record by the Investor. 1315 Capital Management II, LLC ("1315 Capital Management") is the general partner of the Investor. By virtue of such relationship, 1315 Capital Management may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor and 1315 Capital Management disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

On October 11, 2024, the Issuer exchanged all 28,000 existing shares of Series B Shares held by Ampersand 2018 Limited Partnership (the "Investor") for 28,000 newly created shares of Series C Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series C Preferred Shares").

The Series C Preferred Shares are convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by an initial conversion price of $2.02 per share and then multiplied by the number of Series C Preferred Shares to be converted. The Series C Preferred Shares have no expiration date.

These securities are held of record by the Investor. AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

The shares of Series B Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B Preferred Shares") were convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B Preferred Share of $1,000 divided by a conversion price of $6.00 per share (the "Series B Conversion Price") and then multiplied by the number of Series B Preferred Shares to be converted. The Series B Preferred Shares had no expiration date.

On October 11, 2024, the Issuer exchanged all 28,000 existing shares of Series B Shares held by Ampersand 2018 Limited Partnership (the "Investor") for 28,000 newly created shares of Series C Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series C Preferred Shares").

These securities are held of record by the Investor. AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

On July 27, 2024, the reporting person was granted 25,000 restricted stock units, which vested immediately. The restricted stock units convert into common stock on a one-for-one basis.

Represents the net issuance of 15,112 shares from the vesting of 25,000 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 9,888 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

Represents the net issuance of 6,045 shares from the vesting of 10,000 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 3,955 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

The restricted stock units vested immediately.

Represents the net issuance of 7,556 shares from the vesting of 12,500 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 4,944 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

Represents the net issuance of 1,095 shares from the vesting of 1,666 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 571 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

Half of the restricted stock units vested immediately and the remaining half will vest on the six month anniversary of the date of grant.

Represents the net issuance of 7,556 shares from the vesting of 12,500 restricted stock units from which the federal and state withholding due at the vesting of such restricted stock units was satisfied by the issuer withholding 4,944 shares. The reporting person relinquished the shares and the issuer cancelled the shares and returned them to treasury in exchange for remitting federal and state tax withholding obligations of the reporting person resulting from the vesting of restricted stock units. Shares withheld represent an exempt transaction pursuant to Section 16b-3(e). No shares were sold by the reporting person.

The options will vest in three equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service on each such vesting date.

- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.17 to $8.80. The Reporting Person undertakes to provide Interpace Biosciences, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

- These shares are owned by Mr. Burnell's spouse. Mr. Burnell disclaims beneficial ownership of these shares.

The stock options vest and become exercisable over a three-year period, in equal installments, commencing on March 10, 2021, subject to the reporting person's continued service with the Issuer.

The restricted stock units vest annually, in equal installments, over a three-year period, commencing on March 10, 2021.

Each restricted stock unit represents the contingent right to receive one share of common stock of the Issuer.

These Securities are owned by 3K Limited Partnership. The reporting person is the General Partner of the Partnership. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

These Securities are owned by the Peter H. Kamin Childrens Trust dated March 1997. The reporting person is the Trustee of the Trust. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

These Securities are owned by the Peter H. Kamin Revocable Trust dated February 2003. The reporting person is the Trustee of the Trust. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

These Securities are owned by the Peter H. Kamin Revocable Trust dated February 2003. The reporting person is the Trustee of the Trust. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

These Securities are owned by 3K Limited Partnership. The reporting person is the General Partner of the Partnership. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

These Securities are owned by the Peter H. Kamin Childrens Trust dated March 1997. The reporting person is the Trustee of the Trust. The reporting person disclaims beneficial ownership of these Securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such Securities for Section 16 or any other purposes.

The restricted stock is eligible to vest in full on the six-month anniversary of the date of grant, subject to continuous service by Mr. Gorman with the Issuer through such vesting date.

These restricted stock units vest annually in equal installments on each of the first three anniversaries of their date of grant, subject to the reporting person's continued service with the Issuer through the applicable vesting date. Each restricted stock unit represents a right to receive one share of the Issuer's common stock upon vesting.

These restricted stock units vest on the day following a 30 calendar day period in which, for each trading day of such period, a share of the Issuer's common stock has a closing per share price of at least $11.34. Each restricted stock unit represents a right to receive one share of the Issuer's common stock upon vesting.

The options vest immediately.

Restricted stock units convert into common stock on one-for-one basis.

Restricted stock units convert into common stock on one-for-one basis.

On January 29, 2020, the reporting person was granted 5,000 restricted stock units, vesting in full on the six-month anniversary of the date of grant.

The stock option is eligible to vest in equal installments on each of the first three anniversaries of the date of grant.

The stock option is eligible to vest in equal installments on each of the first three anniversaries of the date of grant.

The stock option is eligible to vest in equal installments on each of the first three anniversaries of the date of grant.